Lineage Cell Therapeutics
LCTX
LCTX
117 hedge funds and large institutions have $125M invested in Lineage Cell Therapeutics in 2017 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 40 increasing their positions, 18 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
11% less capital invested
Capital invested by funds: $140M → $125M (-$14.9M)
Holders
117
Holding in Top 10
2
Calls
–
Puts
–
Top Buyers
| 1 | +$5.79M | |
| 2 | +$4.94M | |
| 3 | +$1.74M | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.32M |
| 5 |
AG
Artal Group
Luxembourg
|
+$591K |
Top Sellers
| 1 | -$322K | |
| 2 | -$237K | |
| 3 | -$164K | |
| 4 |
DWM
Destination Wealth Management
Walnut Creek,
California
|
-$140K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$49.1K |